APA (7th ed.) Citation

Wedzicha, J. A., Agusti, A., Brightling, C. E., Calverley, P., Chalmers, J. D., Greening, N., . . . Celli, B. (2026). B15-03 Astegolimab Decreases Exacerbation Risk in Patients With COPD With Frequent Exacerbations, Irrespective of Blood Eosinophil Count: Pooled Analysis of the Pivotal Randomized Trials ALIENTO and ARNASA. American Journal of Respiratory and Critical Care Medicine ; volume 212, issue Supplement_1 ; ISSN 1073-449X 1535-4970. https://doi.org/10.1093/ajrccm/aamag162.1748

Chicago Style (17th ed.) Citation

Wedzicha, J A., et al. "B15-03 Astegolimab Decreases Exacerbation Risk in Patients With COPD With Frequent Exacerbations, Irrespective of Blood Eosinophil Count: Pooled Analysis of the Pivotal Randomized Trials ALIENTO and ARNASA." American Journal of Respiratory and Critical Care Medicine ; Volume 212, Issue Supplement_1 ; ISSN 1073-449X 1535-4970 2026. https://doi.org/10.1093/ajrccm/aamag162.1748.

MLA (9th ed.) Citation

Wedzicha, J A., et al. "B15-03 Astegolimab Decreases Exacerbation Risk in Patients With COPD With Frequent Exacerbations, Irrespective of Blood Eosinophil Count: Pooled Analysis of the Pivotal Randomized Trials ALIENTO and ARNASA." American Journal of Respiratory and Critical Care Medicine ; Volume 212, Issue Supplement_1 ; ISSN 1073-449X 1535-4970, 2026, https://doi.org/10.1093/ajrccm/aamag162.1748.